TY - JOUR
T1 - The perception of teratogenic risk by women with nausea and vomiting of pregnancy
AU - Mazzotta M.s.c, Paolo
AU - Magee, Laura A.
AU - Maltepe M.a, Caroline
AU - Lifshitz, Arielah
AU - Navioz, Yvette
AU - Koren, Gideon
N1 - Funding Information:
This study was supported by an educational grant by Duchesnay, Inc., Laval, Canada, and The Motherisk Research Fund.
PY - 1999
Y1 - 1999
N2 - This study determined the advice reported to be received by women suffering from nausea and vomiting of pregnancy (NVP) from their caregivers regarding management, the teratogenic risk perception of these women and their choice of antiemetic drug use in pregnancy. A secondary objective was to determine prospectively the effect of counseling on malformation risk perception in women with NVP. The women were prospectively followed-up and questioned about the use of pharmacotherapy or other management choices as well as their perception of teratogenic risk through structured telephone interviews. The results showed that at the initial call, around 6 weeks of gestation, over three quarters of the 260 participants reported that therapy of NVP increased their teratogenic risk. This risk perception was decreased significantly after counseling. Women who reported their physicians' advice to change their diet and/or lifestyle attributed an increased risk for major malformations with antiemetics for NVP (P = 0.001), whereas women who reported advice to take antiemetic medications known to be safe to the fetus attributed no change in risk for major malformations with drugs for NVP (P = 0.002). We came to the conclusion that women are commonly hesitant to treat NVP pharmacologically due to unfounded fears of teratogenic risk. Evidenced- based counseling resulted in reduced numbers of women who considered drug therapy for NVP to increase the risk of major malformations.
AB - This study determined the advice reported to be received by women suffering from nausea and vomiting of pregnancy (NVP) from their caregivers regarding management, the teratogenic risk perception of these women and their choice of antiemetic drug use in pregnancy. A secondary objective was to determine prospectively the effect of counseling on malformation risk perception in women with NVP. The women were prospectively followed-up and questioned about the use of pharmacotherapy or other management choices as well as their perception of teratogenic risk through structured telephone interviews. The results showed that at the initial call, around 6 weeks of gestation, over three quarters of the 260 participants reported that therapy of NVP increased their teratogenic risk. This risk perception was decreased significantly after counseling. Women who reported their physicians' advice to change their diet and/or lifestyle attributed an increased risk for major malformations with antiemetics for NVP (P = 0.001), whereas women who reported advice to take antiemetic medications known to be safe to the fetus attributed no change in risk for major malformations with drugs for NVP (P = 0.002). We came to the conclusion that women are commonly hesitant to treat NVP pharmacologically due to unfounded fears of teratogenic risk. Evidenced- based counseling resulted in reduced numbers of women who considered drug therapy for NVP to increase the risk of major malformations.
KW - Antiemetics
KW - Nausea and vomiting of pregnancy
KW - Teratogenic risk
UR - http://www.scopus.com/inward/record.url?scp=0033166315&partnerID=8YFLogxK
U2 - 10.1016/S0890-6238(99)00018-0
DO - 10.1016/S0890-6238(99)00018-0
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 10453916
AN - SCOPUS:0033166315
SN - 0890-6238
VL - 13
SP - 313
EP - 319
JO - Reproductive Toxicology
JF - Reproductive Toxicology
IS - 4
ER -